Next Article in Journal
Interplay between Herpesvirus Infection and Host Defense by PML Nuclear Bodies
Next Article in Special Issue
Retroviral Integration Site Selection
Previous Article in Journal
A Novel Duplex Real-Time Reverse-Transcription PCR Assay for the Detection of Influenza A and the Novel Influenza A(H1N1) Strain
Previous Article in Special Issue
Mutation Rates and Intrinsic Fidelity of Retroviral Reverse Transcriptases
Viruses 2009, 1(3), 1209-1239; doi:10.3390/v1031209
Review

Current and Novel Inhibitors of HIV Protease

1,5
, 2,3
, 1,4
 and 1,4,5,*
1 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 166 10, Prague 6, Czech Republic 2 AIDS Center, Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 120 00, Prague 8, Czech Republic 3 Department of Infectious Diseases, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic 4 Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10, Prague 6, Czech Republic 5 Department of Biochemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43, Prague 2, Czech Republic
* Author to whom correspondence should be addressed.
Received: 8 October 2009 / Revised: 7 December 2009 / Accepted: 7 December 2009 / Published: 11 December 2009
(This article belongs to the Special Issue Retroviral Enzymes)
View Full-Text   |   Download PDF [1044 KB, uploaded 11 December 2009]   |   Browse Figures

Abstract

The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed.
Keywords: HIV protease; protease inhibitors; HAART; resistance development; pharmacokinetic boosting; protease dimerization; alternative inhibitors HIV protease; protease inhibitors; HAART; resistance development; pharmacokinetic boosting; protease dimerization; alternative inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Pokorná, J.; Machala, L.; Řezáčová, P.; Konvalinka, J. Current and Novel Inhibitors of HIV Protease. Viruses 2009, 1, 1209-1239.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert